Moderna (MRNA) reported better-than-expected Q4 2025 financials on Friday and reaffirmed its 2026 growth target even as the vaccine maker suffered a major regulatory setback for its flu shot candidate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results